Rabbit Anticoagulant Activity Test: Principles, Methods, and Applications in Medical Device Hemocomp

The rabbit anticoagulant activity test is a specialized hemocompatibility study used to assess whether medical device materials or their extractable substances interfere with the blood coagulation system. Performed in accordance with ISO 10993-4 and GB/T 16886.4, the test measures key coagulation parameters in rabbit blood to identify anticoagulant leachables and support biological safety evaluations for regulatory submission.

Technical Overview

The rabbit anticoagulant activity test is an in vitro laboratory study designed to determine whether a test material, a medical device, or substances leaching from them can inhibit or otherwise alter the blood coagulation cascade. The test is a recognized component of hemocompatibility evaluation within the framework of biological risk assessment for medical devices that contact circulating blood, either directly or indirectly.

The study is performed in conformance with ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood) and its Chinese national equivalent GB/T 16886.4. Test planning and sample preparation typically also reference ISO 10993-12 for extract preparation and ISO 10993-2 for animal welfare requirements. Rabbit blood is a preferred test system because the rabbit coagulation cascade closely resembles the human pathway, healthy animals provide consistent baseline coagulation values, and sufficient blood volume can be collected from a single animal for replicate testing.

During the assay, rabbit whole blood or platelet-poor plasma is brought into contact with the test sample or its extract. Coagulation function is then quantified using standard clotting assays. A statistically significant prolongation of clotting times relative to negative controls indicates that the sample releases substances with anticoagulant activity, which must be addressed in the overall biological safety assessment of the device.

Testing Samples

Blood-Contacting Medical Devices

Devices intended for direct or indirect contact with circulating blood are the primary candidates for this test. Typical examples include intravascular catheters, guidewires, vascular stents, vascular grafts, oxygenators, hemodialyzers, blood filters, extracorporeal circulation tubing sets, and blood storage containers.

Surface-Modified and Coated Materials

Products bearing antithrombotic or hydrophilic surface treatments, such as heparin-bonded coatings, are evaluated to characterize the anticoagulant effect of the functionalized surface and to confirm coating behavior under standardized contact conditions.

Extracts and Test Solutions

For materials that cannot be tested in direct contact configuration, aqueous and non-aqueous extracts are prepared according to ISO 10993-12 using documented extraction ratios, temperatures, and durations. The extracts are then mixed with rabbit plasma to screen for leachable substances that influence coagulation.

Testing Items

The core testing panel covers the coagulation parameters most sensitive to circulating and surface-bound anticoagulant effects:

• Activated Partial Thromboplastin Time (APTT) — evaluates the intrinsic coagulation pathway and is highly sensitive to heparin-like activity.
• Prothrombin Time (PT) — evaluates the extrinsic coagulation pathway.
• Thrombin Time (TT) — measures the conversion of fibrinogen to fibrin and detects interference at the final common pathway.
• Fibrinogen concentration (FIB) — quantifies the functional fibrinogen level after sample contact.
• Supplementary endpoints such as whole-blood clotting time or platelet count, where required by the device-specific risk profile.

Testing Methods

Test System and Animal Requirements

Healthy adult rabbits, commonly New Zealand white rabbits, are housed and handled under institutionally approved animal care procedures consistent with ISO 10993-2 and GB/T 16886.2. Animals are screened to confirm baseline coagulation values within normal physiological ranges before enrollment in the study. Blood is collected using a minimally invasive procedure, typically from the central ear artery, and anticoagulated with trisodium citrate at a defined blood-to-anticoagulant ratio.

Sample Preparation and Contact Procedure

Test samples are cleaned, sterilized by the method intended for clinical use, and prepared at standardized surface-area-to-volume ratios. Plasma or whole blood is incubated with the test sample or mixed with the prepared extract under controlled temperature and time conditions, commonly 37 °C for a contact period defined in the study protocol. Parallel incubations are performed with a negative reference material and a positive control such as heparin sodium to demonstrate assay sensitivity.

Coagulation Parameter Measurement

Following the contact period, APTT, PT, TT, and FIB are measured on a calibrated semi-automated or automated coagulation analyzer using validated reagent systems. All measurements are performed in replicate, and the coagulation analyzer is verified with normal and abnormal control plasmas before each analytical run.

Data Evaluation and Interpretation

Results for the test group are compared with the negative control group using appropriate statistical methods. A significant prolongation of APTT, PT, or TT, or a marked reduction in fibrinogen concentration, indicates anticoagulant activity associated with the test sample. Findings are interpreted in the context of the device's intended clinical use, contact duration, and the overall ISO 10993-1 biological evaluation plan.

Applications

The rabbit anticoagulant activity test supports multiple objectives across product development and regulatory compliance:

• Biological safety evaluation of blood-contacting devices for regulatory submissions in China (NMPA), the United States (FDA), and the European Union under the MDR.
• Verification of anticoagulant performance for heparin-coated and other surface-modified blood-contacting products.
• Screening of novel polymeric, metallic, and hybrid biomaterials during early-stage material selection.
• Investigation of extractable and leachable substances that may affect coagulation following sterilization, packaging, or process changes.
• Support for equivalence assessments when materials, suppliers, or manufacturing processes are modified.

FAQ

Why is rabbit blood used instead of human blood?

Rabbit blood provides a reproducible and ethically manageable test system with a coagulation cascade highly comparable to that of humans, and it permits collection of adequate volume with controlled donor variables. Human donor blood introduces variability in medication status and individual coagulation baselines, whereas purpose-bred rabbits deliver greater batch-to-batch consistency.

What does a prolonged APTT result indicate?

A significant prolongation of APTT relative to the negative control suggests that the sample releases substances acting on the intrinsic pathway, which is the classic response to heparin-like activity. The result prompts further chemical characterization of leachables and a benefit-risk review within the biological evaluation.

Is the test performed only on finished devices?

No. The test can be conducted on finished sterilized devices, representative material coupons, or extracts prepared according to ISO 10993-12. The choice depends on the device geometry, the intended blood contact configuration, and the risk analysis documented in the biological evaluation plan.

How long does a typical study take?

Depending on sample preparation, sterilization requirements, and the number of test groups, an accredited third-party laboratory generally completes the study within two to four weeks after sample receipt, including analytical runs and report issuance.

Can the test be combined with other hemocompatibility endpoints?

Yes. The rabbit anticoagulant activity test is frequently performed alongside thrombosis testing, hemolysis testing per ASTM F756 and GB/T 16886.4, complement activation, and platelet function assays to construct a complete ISO 10993-4 interaction-with-blood profile for the device.